# Richard T. Penson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-t-penson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,700 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 68 |
| i10-index | 179 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5089955620 |
| ORCID iD | https://orcid.org/0000-0002-8091-8588 |
| Works | 394 |

## Researcher papers

- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Improved Survival with Bevacizumab in Advanced Cervical Cancer](https://scholariq.org/papers/improved-survival-with-bevacizumab-in-advanced-cervical-cancer/)
- [Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer](https://scholariq.org/papers/phase-ii-study-of-bevacizumab-in-patients-with-platinum-resistant-ovarian-cancer/)
- [Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)](https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)
- [Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)
- [Ovarian Cancer, Version 3.2012](https://scholariq.org/papers/ovarian-cancer-version-3-2012/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Palliative Care and End-of-Life Issues](https://scholariq.org/topics/palliative-care-and-end-of-life-issues/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.